*Corresponding author: NHO 宇多野病院多発性硬化症センター〔〒 616-8255 京都市右京区鳴滝音戸山 8〕 1) NHO 宇多野病院多発性硬化症センター (Received December 2, 2014; Accepted April 7, 2015; Published online in J-STAGE on July 7, 2015) doi: 10.5692/clinicalneurol.cn-000690
55:538
臨床神経学 55 巻 8 号(2015:8)
Table 1 The PML risks based on the duration of treatment and previous exposure to immunosuppression. NTZ exposure
Fig. 1 Annualized relapse rate in STRATA study. The annualized relapse rate in TOP (Tysabri Observational Program) study64) also decreased from 1.99 of baseline to 0.24 after 48–60 months treatment.
Multiple sclerosis is a neurodegenerative and inflammatory immune disorder in the central nervous system (CNS). Most patients show relapse-remitting c...